Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination

European Journal of Ophthalmology

Volumn 15, Issue 3, 2005, Pages 336-342

  Day, D G ^a   Sharpe, E D ^b   Beischel, C J ^c   Jenkins, J N ^d   Stewart, J A ^d   Stewart, William C ^d,e  

^a Omni Eye Services   (United States)

^b Ophthalmology Consultants   (United States)

^c Kulze and Beischel   (United States)

^d University of South Carolina   (United States)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bimatoprost; Dorzolamide timolol; Glaucoma; Ocular hypertension

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL;

ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; VISUAL IMPAIRMENT;

EID: 21744459520     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500304     Document Type: Article

References (21)

1. Stewart WC. New perspectives in the medical treatment of glaucoma. Current Opinion Ophthalmol 1999; 127: 142-7.
2. Clineshmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 17-24.
3. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 10-6.
4. Fechtner R, Clineschmidt C, Getson A, Adamsons IA, for the Cosopt Study Group. A Three Month, Parallel, Randomized, Observer-Masked, Multicenter study Comparing Cosopt to Xalatan in Patients with Elevated IOP. Invest Ophthalmol Vis Sci 1999; 40 (Suppl): S665.
5. Konstas AGP, Papapanos P, Tersis I, Houliara D, Stewart WC. 24-hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol/dorzolamide fixed combination. Ophthalmology 2003; 110: 1357-60.
6. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol 2001; 45 (Suppl): S353-60.
7. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55-63.
8. Book SA. Essentials of statistics. In: Arthur AA, Rogers JL, Bradley JW (eds). Testing Statistical Hypotheses. New York: McGraw-Hill Book Company, 1978; 117-22.
9. Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA, Stewart WC. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocular Pharm Therap 1998; 14: 129-35.
10. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmol (Copenh) 1987; 65: 618-21.
11. Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily vs. timolol gel in treating elevated IOP. J Glaucoma 1998; 7: 402-7.
12. Stewart WC, Sharpe ED, Harbin TS Jr, Pastor SA, Day DG, Holmes KT, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure. Am J Ophthalmol 2000; 129: 723-7.
13. Siegel S. Non-Parametric Statistics for the Behavioral Sciences, 1st ed. Series in Psychology. New York: McGraw-Hill Book Company, 1956; 63-7.
14. Woodward DF, Krauss AHP, Chen J, Lai RK, Spada CS, Burk RM, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001; 45 (Suppl): S337-45.
15. Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J, Liang Y, Wheeler LA. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev 2004; 22: 103-20.
16. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001; 432: 211-3.
17. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003; 19: 501-15.
18. Palkovits M. The brain and the pain: neurotransmitters and neuronal pathways of pain perception and response. Orv Hetil 2000; 141: 2231-9.
19. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45 (Suppl): S361-8.
20. Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106: 1024-9.
21. Strahlman E, Tipping R, Vogel R. A double masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995; 113: 1009-16.